Recombinant multi-species ADC/AZIN2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ADC/AZIN2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene belongs to the antizyme inhibitor family, which plays a role in cell growth and proliferation by maintaining polyamine homeostasis within the cell. Antizyme inhibitors are homologs of ornithine decarboxylase (ODC, the key enzyme in polyamine biosynthesis) that have lost the ability to decarboxylase ornithine; however, retain the ability to bind to antizymes. Antizymes negatively regulate intracellular polyamine levels by binding to ODC and targeting it for degradation, as well as by inhibiting polyamine uptake. Antizyme inhibitors function as positive regulators of polyamine levels by sequestering antizymes and neutralizing their effect. This gene encodes antizyme inhibitor 2, the second member of this gene family. Like antizyme inhibitor 1, antizyme inhibitor 2 interacts with all 3 antizymes and stimulates ODC activity and polyamine uptake. However, unlike antizyme inhibitor 1, which is ubiquitously expressed and localized in the nucleus and cytoplasm, antizyme inhibitor 2 is predominantly expressed in the brain and testis and localized in the endoplasmic reticulum-golgi intermediate compartment. Recent studies indicate that antizyme inhibitor 2 is also expressed in specific cell types in ovaries, adrenal glands and pancreas, and in mast cells. The exact function of this gene is not known, however, available data suggest its role in cell growth, spermiogenesis, vesicular trafficking and secretion. Accumulation of antizyme inhibitor 2 has also been observed in brains of patients with Alzheimer's disease. There has been confusion in literature and databases over the nomenclature of this gene, stemming from an earlier report that a human cDNA clone (identical to ODCp/AZIN2) had arginine decarboxylase (ADC) activity (PMID:14738999). Subsequent studies in human and mouse showed that antizyme inhibitor 2 was devoid of arginine decarboxylase activity (PMID:19956990). Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Sep 2014]
The Alternative Names of target: 4933429I20Rik,ADC,ARGDC),AZI2,AZIB1,AZIN2,Adc,Antizyme inhibitor 2,Arginine decarboxylase (ADC,AzI2,Azi2,Azin2,B930082O19,ODC-p,ODC1L,ODCp,Odcp,Ornithine decarboxylase-like protein (ODC-like protein),RGD1564776,ornithine decarboxylase paralog (ODC-p)

Target products collectionGo to ADC/AZIN2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP4134-Ag-1/ GM-Tg-hg-IP4134-Ag-2 Human ADC/AZIN2 protein Human
GM-Tg-rg-IP4134-Ag-1/ GM-Tg-rg-IP4134-Ag-2 Rat ADC/AZIN2 protein Rat
GM-Tg-mg-IP4134-Ag-1/ GM-Tg-mg-IP4134-Ag-2 Mouse ADC/AZIN2 protein Mouse
GM-Tg-cynog-IP4134-Ag-1/ GM-Tg-cynog-IP4134-Ag-2 Cynomolgus/Rhesus macaque ADC/AZIN2 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP4134-Ag-1/ GM-Tg-felg-IP4134-Ag-2 Feline ADC/AZIN2 protein Feline
GM-Tg-cang-IP4134-Ag-1/ GM-Tg-cang-IP4134-Ag-2 Canine ADC/AZIN2 protein Canine
GM-Tg-bovg-IP4134-Ag-1/ GM-Tg-bovg-IP4134-Ag-2 Bovine ADC/AZIN2 protein Bovine
GM-Tg-equg-IP4134-Ag-1/ GM-Tg-equg-IP4134-Ag-2 Equine ADC/AZIN2 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP4134-Ag-1/ GM-Tg-hg-IP4134-Ag-2; GM-Tg-rg-IP4134-Ag-1/ GM-Tg-rg-IP4134-Ag-2;
GM-Tg-mg-IP4134-Ag-1/ GM-Tg-mg-IP4134-Ag-2; GM-Tg-cynog-IP4134-Ag-1/ GM-Tg-cynog-IP4134-Ag-2;
GM-Tg-felg-IP4134-Ag-1/ GM-Tg-felg-IP4134-Ag-2; GM-Tg-cang-IP4134-Ag-1/ GM-Tg-cang-IP4134-Ag-2;
GM-Tg-bovg-IP4134-Ag-1/ GM-Tg-bovg-IP4134-Ag-2; GM-Tg-equg-IP4134-Ag-1/ GM-Tg-equg-IP4134-Ag-2
Products Name ADC/AZIN2 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name ADC/AZIN2
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ADC/AZIN2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.